Advances in pancreatic cancer

Current Opinion in Gastroenterology

Volumn 27, Issue 5, 2011, Pages 460-466

  Kim, Edward J ^a   Simeone, Diane M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cancer stem cells; cancer associated fibroblasts; pancreatic cancer; stroma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLERIXAFOR; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL HYPOXIA; CELLULAR IMMUNITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FIBROBLAST; GENETIC HETEROGENEITY; HUMAN; PANCREAS CANCER; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CELL HYPOXIA; CHEMOKINE CXCL12; FIBROBLASTS; HEDGEHOG PROTEINS; HUMANS; IMMUNITY, CELLULAR; PANCREAS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 80051794576     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328349e31f     Document Type: Review

References (59)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403-13.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
4. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28:4010.
5. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010; 304:1073-1081.
6. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-1210.
7. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297:267-277.
8. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008; 299:1019-1026.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
11. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell 2010; 18:884-901.
12. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007; 194:S84-S86.
13. Pandol S, Edderkaoui M, Gukovsky I, et al. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2009; 7:S44-S47.
14. Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate cells. J Gastroenterol 2009; 44:249-260.
15. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19:257-272.
16. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 2010; 21:19-25.
17. Ikenaga N, Ohuchida K, Mizumoto K, et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010; 139:1041-1051; 51 e1-8. This study identifies a subpopulation of CAFs based on CD10 expression that support tumor growth and could be a potential therapeutic target.
18. Farrow B, Rowley D, Dang T, Berger DH. Characterization of tumor-derived pancreatic stellate cells. J Surg Res 2009; 157:96-102.
19. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68:918-926.
20. Kikuta K, Masamune A, Watanabe T, et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010; 403:380-384.
21. Fujita H, Ohuchida K, Mizumoto K, et al. Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 2010; 39:1254-1262.
22. Xu Z, Vonlaufen A, Phillips PA, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 2010; 177:2585-2596.
23. Gao Z, Wang X, Wu K, et al. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/ CXCR4 axis. Pancreatology 2010; 10:186-193.
24. Marechal R, Demetter P, Nagy N, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009; 100:1444-1451.
25. Saur D, Seidler B, Schneider G, et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005; 129:1237-1250.
26. Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy. Br J Cancer 2010; 103:1671-1679.
27. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-323.
28. Dosch JS, Pasca di Magliano M, Simeone DM. Pancreatic cancer and hedgehog pathway signaling: New insights. Pancreatology 2010; 10:151-157.
29. Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. Science 2007; 317:372-376.
30. Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009; 28:3513-3525.
31. Seeley ES, Carriere C, Goetze T, et al. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 2009; 69:422-430.
32. Lauth M, Bergstrom A, Shimokawa T, et al. DYRK1B-dependent autocrine-toparacrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol 2010; 17:718-725. This study provides a novel mechanistic explanation for differential Hedgehog pathway signaling in cancer cells and supporting stroma.
33. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2009; 106:4254-4259.
34. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008; 455:406-410.
35. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-1461.
36. ChangQ, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically-grown primary xenografts of human pancreatic cancer. Cancer Res 2011; 71:3110-3120.
37. Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-5517.
38. Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005; 46:668-676.
39. Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009; 11:497-508.
40. Cheng BQ, Segersvard R, Permert J, Wang F. Pancreatic cancer cells expressing hypoxia-inducible factor-1alpha tend to be adjacent to intratumoral blood vessels. Eur Surg Res 2010; 45:134-137.
41. Zhang JJ, Wu HS, Wang L, et al. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010; 16:2881-2888.
42. Onozuka H, Tsuchihara K, Esumi H. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci 2011; 102:975-982.
43. Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 2011; 102:1144-1150.
44. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67:9518-9527.
45. Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NFkappaB- dependent manner. Cancer Cell 2010; 17:135-147.
46. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330:827-830. This study highlights importance of an FAP+ subpopulation of stromal cells that are immunosuppressive, making them a potential therapeutic target for inhibition, thus allowing immune activation against tumors.
47. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-1616. This study explored efficacy of a CD40 agonist to reverse immune suppression and showed moderate clinical response.
48. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988.
49. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-10951.
50. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110.
51. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104:973-978.
52. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13:153-166.
53. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-1037.
54. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3:e2428.
55. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672-679.
56. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806.
57. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467:1114-1117. This study is the first to generate a timeline of tumor development and progression that details greater than a decade between tumor initiation and development of metastatic capabilities. This would suggest metastasis as a relatively late event suggesting potential opportunities for earlier detection.
58. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467:1109-1113. This study confirms significant heterogeneity within an individual tumor with different sites of metastasis carrying different driver mutations. This observation carries significant implications for future attempts to deliver 'tailored' therapy and the limitations of characterizing a single site biopsy to assign a specific therapy.
59. Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011; 223:295-306.